Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Epix Pharmaceuticals has received marketing approval for its blood pool magnetic resonance angiography agent, Vasovist, in South Korea.
Subscribe to our email newsletter
Vasovist is an injectable intravascular contrast agent designed to provide improved imaging of the vascular system through magnetic resonance angiography imaging (MRA). Vasovist has been approved for marketing in 34 countries, including all 27 member states of the EU, Switzerland, Turkey, Australia and Canada.
The marketing rights to Vasovist are held by Bayer Schering Pharma in Europe and by Bayer HealthCare Pharmaceuticals in the US and Canada. Both companies are part of Bayer AG.
Michael Kauffman, CEO of EPIX, said: “We remain hopeful for approval of Vasovist in the US by the end of 2008 and, as previously announced, recently resubmitted a new drug application for Vasovist to the FDA.”